Fidelity Investments
PGNX

Fidelity Investments’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Fidelity Investments’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,278,929
Closed -$8.02M – 4384
2018
Q3 		$8.02M Sell
1,278,929
-198,300
-13% -$1.52M ﹤0.01% 1996
2018
Q2 		$11.9M Buy
1,477,229
+5,000
+0.3% +$38.2K ﹤0.01% 1898
2018
Q1 		$11M Sell
1,472,229
-382,927
-21% -$2.55M ﹤0.01% 1937
2017
Q4 		$11M Sell
1,855,156
-592,000
-24% -$3.6M ﹤0.01% 1924
2017
Q3 		$18M Sell
2,447,156
-223,040
-8% -$1.42M ﹤0.01% 1730
2017
Q2 		$18.1M Sell
2,670,196
-317,930
-11% -$2.35M ﹤0.01% 1719
2017
Q1 		$28.2M Sell
2,988,126
-592,030
-17% -$5.91M ﹤0.01% 1549
2016
Q4 		$30.9M Buy
3,580,156
+119,000
+3% +$880K ﹤0.01% 1505
2016
Q3 		$21.9M Buy
3,461,156
+117,933
+4% +$713K ﹤0.01% 1634
2016
Q2 		$14.1M Sell
3,343,223
-933,056
-22% -$4.51M ﹤0.01% 1822
2016
Q1 		$18.6M Sell
4,276,279
-966,000
-18% -$4.3M ﹤0.01% 1690
2015
Q4 		$32.1M Sell
5,242,279
-89,872
-2% -$589K ﹤0.01% 1445
2015
Q3 		$30.5M Buy
5,332,151
+89,872
+2% +$690K ﹤0.01% 1474
2015
Q2 		$39.1M Sell
5,242,279
-212,267
-4% -$1.28M 0.01% 1446
2015
Q1 		$32.6M Buy
5,454,546
+212,267
+4% +$1.34M ﹤0.01% 1537
2014
Q4 		$39.6M Buy
5,242,279
+198,737
+4% +$1.19M 0.01% 1442
2014
Q3 		$26.2M Buy
5,043,542
+967,496
+24% +$4.82M ﹤0.01% 1627
2014
Q2 		$17.6M Sell
4,076,046
-329,900
-7% -$1.26M ﹤0.01% 1853
2014
Q1 		$18M Sell
4,405,946
-1,765,100
-29% -$9.03M ﹤0.01% 1805
2013
Q4 		$32.9M Sell
6,171,046
-2,587,300
-30% -$11.4M ﹤0.01% 1513
2013
Q3 		$44.1M Buy
8,758,346
+255,100
+3% +$1.38M 0.01% 1357
2013
Q2 		$37.9M Buy
+8,503,246
New +$38.2M 0.01% 1375

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Fidelity Investments's PGNX Position: Q4 2018 in Review

Fidelity Investments sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 1,278,929 shares — an estimated $8.02M sold.

Fidelity Investments first reported a position in PGNX in Q2 2013 and held it in 22 quarters. The position peaked at $44.1M in Q3 2013. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Fidelity Investments reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Fidelity Investments sold 1,278,929 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $8.02M.
  • Fidelity Investments first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
  • Fidelity Investments's Progenics Pharmaceuticals Inc position peaked at $44.1M in Q3 2013.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Fidelity Investments's 13F filing for Q4 2018, filed 13 Feb 2019.